Review



bivalent bnt162b2  (Pfizer Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pfizer Inc bivalent bnt162b2
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc13154980-26-8-11?v=Pfizer+Inc
    Average 86 stars, based on 1 article reviews
    bivalent bnt162b2 - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants"

    Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

    Journal: Human Vaccines & Immunotherapeutics

    doi: 10.1080/21645515.2026.2638022

    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Figure Legend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Techniques Used: Comparison, Infection



    Similar Products

    bivalent bnt162b2  (Pfizer Inc)
    86
    Pfizer Inc bivalent bnt162b2
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc13154980-26-8-11?v=Pfizer+Inc
    Average 86 stars, based on 1 article reviews
    bivalent bnt162b2 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent omicron ba.1-containing vaccine  (Pfizer Inc)
    90
    Pfizer Inc bnt162b2 bivalent omicron ba.1-containing vaccine
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Bivalent Omicron Ba.1 Containing Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc10101054__reviewer___comments-78-46-41?v=Pfizer+Inc
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent omicron ba.1-containing vaccine - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.1 bivalent booster  (BioNTech)
    90
    BioNTech bnt162b2 ba.1 bivalent booster
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Ba.1 Bivalent Booster, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc12197680-32-3-20?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.1 bivalent booster - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.4/5 bivalent booster  (BioNTech)
    90
    BioNTech bnt162b2 ba.4/5 bivalent booster
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Ba.4/5 Bivalent Booster, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc12197680-33-6-20?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.4/5 bivalent booster - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent (ba.4/ba.5)  (BioNTech)
    90
    BioNTech bnt162b2 bivalent (ba.4/ba.5)
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Bivalent (Ba.4/Ba.5), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc12112343-48-11-5?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent (ba.4/ba.5) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent wt/omi ba.1  (BioNTech)
    90
    BioNTech bnt162b2 bivalent wt/omi ba.1
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent Wt/Omi Ba.1, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc12001871-452-7-17?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent wt/omi ba.1 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent wt/omi ba.4/ba.5  (BioNTech)
    90
    BioNTech bnt162b2 bivalent wt/omi ba.4/ba.5
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent Wt/Omi Ba.4/Ba.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc12001871-452-8-17?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent wt/omi ba.4/ba.5 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent  (BioNTech)
    90
    BioNTech bnt162b2 bivalent
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pmc11961057-250-22-21?v=BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra  (Abbott Laboratories)
    90
    Abbott Laboratories bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Ba.4/5 Bivalent Booster With Iiv4 Influvac Tetra, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/pm40333241-320-0-8?v=Abbott+Laboratories
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty  (Pfizer Inc)
    90
    Pfizer Inc bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bivalent Bnt162b2 Ba.1 Or Ba.4/5 Mrna Comirnaty, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/10__1016_slash_s2352___3026_ascii40_25_ascii41_00008___0-57-19-27?v=Pfizer+Inc
    Average 90 stars, based on 1 article reviews
    bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Journal: Human Vaccines & Immunotherapeutics

    Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

    doi: 10.1080/21645515.2026.2638022

    Figure Lengend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Article Snippet: In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines.

    Techniques: Comparison, Infection

    <xref ref-type= Thomas 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Thomas 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Biomarker Discovery, Vaccines, Comparison, Saline, Injection

    <xref ref-type= Zhao 2024 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Zhao 2024

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Hayashi 2023 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Hayashi 2023

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Lau 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Lau 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Leuva 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Leuva 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Thomas 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Thomas 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Biomarker Discovery, Vaccines, Comparison, Saline, Injection

    <xref ref-type= Zhao 2024 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Zhao 2024

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Hayashi 2023 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Hayashi 2023

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Lau 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Lau 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Leuva 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Leuva 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection